Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
REGENXBIO Inc. et al v. Sarepta Therapeutics, Inc., et al.
Case Number:
1:20-cv-01226
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 05, 2024
Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid
A Delaware judge found a gene therapy patent at the center of an infringement suit against Sarepta, brought by the University of Pennsylvania, was ineligible for patent protection because the claims cover a combination of two recombinant DNA sequences that are already naturally occurring.
-
January 04, 2022
No 'Safe Harbor' For Gene Therapy Found In Hatch-Waxman
A Delaware federal judge told Massachusetts biotechnology company Sarepta on Tuesday that it could not use the "safe harbor" provisions of the Hatch-Waxman Act to protect a gene therapy it is developing with Roche to treat muscular dystrophy from a patent infringement lawsuit by the University of Pennsylvania.
-
December 16, 2021
IP Forecast: Feds To Spar With Gilead Over CEO's Testimony
Gilead Sciences will ask a Delaware federal judge next week to block the federal government from deposing the pharmaceutical company's CEO in a high-profile patent case over allegations Gilead made billions by selling HIV medications using research funded by taxpayers. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.